{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:03:03Z","timestamp":1790276583670,"version":"4.1.0"},"reference-count":38,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2012.0584","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T05:20:04Z","timestamp":1525238404000},"source":"Crossref","is-referenced-by-count":3,"title":["The Therapeutic Potential of Intraocular Depot Steroid Systems"],"prefix":"10.3238","author":[{"given":"Martin M.","family":"Nentwich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Ulbig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2012,9,14]]},"reference":[{"key":"10.3238\/arztebl.2012.0584_ref1","doi-asserted-by":"crossref","unstructured":"Cunha-Vaz J, Bernardes R, Lobo C: Blood-retinal barrier. Eur J Ophthalmol 2010; 21: 3\u20139.","DOI":"10.5301\/EJO.2010.6049"},{"key":"10.3238\/arztebl.2012.0584_ref2","doi-asserted-by":"crossref","unstructured":"Urtti A: Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 2006; 58: 1131\u20135.","DOI":"10.1016\/j.addr.2006.07.027"},{"key":"10.3238\/arztebl.2012.0584_ref3","doi-asserted-by":"crossref","unstructured":"Fischer N, Narayanan R, Loewenstein A, Kuppermann BD: Drug delivery to the posterior segment of the eye. Eur J Ophthalmol 2010; 21: 20\u20136.","DOI":"10.5301\/EJO.2010.6051"},{"key":"10.3238\/arztebl.2012.0584_ref4","doi-asserted-by":"crossref","unstructured":"Moshfeghi AA, Rosenfeld PJ, Flynn HW Jr., et al.: Endophthalmitis after intravitreal anti-vascular endothelial growth factor antagonists: a six-year experience at a university referral center. Retina 2011; 31: 662\u20138.","DOI":"10.1097\/IAE.0b013e31821067c4"},{"key":"10.3238\/arztebl.2012.0584_ref5","doi-asserted-by":"crossref","unstructured":"Sampat KM, Garg SJ: Complications of intravitreal injections. Curr Opin Ophthalmol 2010; 21: 178\u201383.","DOI":"10.1097\/ICU.0b013e328338679a"},{"key":"10.3238\/arztebl.2012.0584_ref6","doi-asserted-by":"crossref","unstructured":"Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T: Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009; 116: 57\u201365 e5.","DOI":"10.1016\/j.ophtha.2008.10.018"},{"key":"10.3238\/arztebl.2012.0584_ref7","doi-asserted-by":"crossref","unstructured":"Hayashi K, Hayashi H: Intravitreal versus retrobulbar injections of triamcinolone for macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2005; 139: 972\u201382.","DOI":"10.1016\/j.ajo.2004.12.087"},{"key":"10.3238\/arztebl.2012.0584_ref8","doi-asserted-by":"crossref","unstructured":"Scholl S, Augustin A, Loewenstein A, Rizzo S, Kupperman B: General pathophysiology of macular edema. Eur J Ophthalmol 2010; 21: 10\u20139.","DOI":"10.5301\/EJO.2010.6050"},{"key":"10.3238\/arztebl.2012.0584_ref9","doi-asserted-by":"crossref","unstructured":"Glacet-Bernard A, Coscas G, Zourdani A, Soubrane G, Souied EH: Steroids and macular edema from retinal vein occlusion. Eur J Ophthalmol 2010; 21: 37\u201344.","DOI":"10.5301\/EJO.2010.6053"},{"key":"10.3238\/arztebl.2012.0584_ref10","unstructured":"Kollias AN, Ulbig MW: Diabetic retinopathy: Early diagnosis and effective treatment. Dtsch Arztebl Int 2010; 107(5): 75\u201383; quiz 4."},{"key":"10.3238\/arztebl.2012.0584_ref11","doi-asserted-by":"crossref","unstructured":"Herrero-Vanrell R, Cardillo JA, Kuppermann BD: Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema. Clin Ophthalmol 2011; 5: 139\u201346.","DOI":"10.2147\/OPTH.S15783"},{"key":"10.3238\/arztebl.2012.0584_ref12","doi-asserted-by":"crossref","unstructured":"Kohner EM, Laatikainen L, Oughton J: The management of central retinal vein occlusion. Ophthalmology 1983; 90: 484\u20137.","DOI":"10.1016\/S0161-6420(83)34527-9"},{"key":"10.3238\/arztebl.2012.0584_ref13","doi-asserted-by":"crossref","unstructured":"Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL: Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol 2008; 126: 1191\u2013201.","DOI":"10.1001\/archopht.126.9.1191"},{"key":"10.3238\/arztebl.2012.0584_ref14","doi-asserted-by":"crossref","unstructured":"Kempen JH, Altaweel MM, Holbrook JT, et al.: Randomized Comparison of Systemic Anti-inflammatory Therapy Versus Fluocinolone Acetonide Implant for Intermediate, Posterior, and Panuveitis: The Multicenter Uveitis Steroid Treatment Trial. Ophthalmology 2011; 118: 1916\u201326.","DOI":"10.1016\/j.ophtha.2011.07.027"},{"key":"10.3238\/arztebl.2012.0584_ref15","doi-asserted-by":"crossref","unstructured":"Pearson PA, Comstock TL, Ip M, Callanan D, et al.: Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology 2011; 118: 1580\u20137.","DOI":"10.1016\/j.ophtha.2011.02.048"},{"key":"10.3238\/arztebl.2012.0584_ref16","doi-asserted-by":"crossref","unstructured":"Jain N, Stinnett SS, Jaffe GJ: Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion thirty-six-month results. Ophthalmology 2012; 119: 132\u20137.","DOI":"10.1016\/j.ophtha.2011.06.019"},{"key":"10.3238\/arztebl.2012.0584_ref17","doi-asserted-by":"crossref","unstructured":"Campochiaro PA, Brown DM, Pearson A, et al.: Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011; 118: 626\u201335 e2.","DOI":"10.1016\/j.ophtha.2010.12.028"},{"key":"10.3238\/arztebl.2012.0584_ref18","doi-asserted-by":"crossref","unstructured":"Bandello F, Iacono P, Battaglia Parodi M: Treatment options for diffuse diabetic macular edema. Eur J Ophthalmol 2010; 21: 45\u201350.","DOI":"10.5301\/EJO.2010.6054"},{"key":"10.3238\/arztebl.2012.0584_ref19","doi-asserted-by":"crossref","unstructured":"Ip MS, Scott IU, VanVeldhuisen PC, et al.: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009; 127: 1101\u201314.","DOI":"10.1001\/archophthalmol.2009.234"},{"key":"10.3238\/arztebl.2012.0584_ref20","doi-asserted-by":"crossref","unstructured":"Scott IU, Ip MS, VanVeldhuisen PC, et al.: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009; 127: 1115\u201328.","DOI":"10.1001\/archophthalmol.2009.233"},{"key":"10.3238\/arztebl.2012.0584_ref21","doi-asserted-by":"crossref","unstructured":"Winterhalter S, Ruokonen P, van der Velden KH, Pleyer U, Joussen AM: Intravitreal implants: drug carriers and carriers of hope? Ophthalmologe 2011; 108: 222\u20139.","DOI":"10.1007\/s00347-010-2264-y"},{"key":"10.3238\/arztebl.2012.0584_ref22","doi-asserted-by":"crossref","unstructured":"Gan IM, Ugahary LC, van Dissel JT, van Meurs JC: Effect of intravitreal dexamethasone on vitreous vancomycin concentrations in patients with suspected postoperative bacterial endophthalmitis. Graefes Arch Clin Exp Ophthalmol 2005; 243: 1186\u20139.","DOI":"10.1007\/s00417-005-1182-1"},{"key":"10.3238\/arztebl.2012.0584_ref23","doi-asserted-by":"crossref","unstructured":"Haller JA, Bandello F, Belfort R, et al.: Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117: 1134\u201346 e3.","DOI":"10.1016\/j.ophtha.2010.03.032"},{"key":"10.3238\/arztebl.2012.0584_ref24","doi-asserted-by":"crossref","unstructured":"Haller JA, Bandello F, Belfort R, et al.: Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011; 118: 2453\u201360.","DOI":"10.1016\/j.ophtha.2011.05.014"},{"key":"10.3238\/arztebl.2012.0584_ref25","doi-asserted-by":"crossref","unstructured":"Lowder C, Belfort R Jr., Lightman S, et al.: Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011; 129: 545\u201353.","DOI":"10.1001\/archophthalmol.2010.339"},{"key":"10.3238\/arztebl.2012.0584_ref26","doi-asserted-by":"crossref","unstructured":"Finger RP, Fimmers R, Holz FG, Scholl HP: Incidence of blindness and severe visual impairment in Germany: projections for 2030. Invest Ophthalmol Vis Sci 2011; 52: 4381\u20139.","DOI":"10.1167\/iovs.10-6987"},{"key":"10.3238\/arztebl.2012.0584_ref27","doi-asserted-by":"crossref","unstructured":"Finger RP, Fimmers R, Holz FG, Scholl HP: Prevalence and causes of registered blindness in the largest federal state of Germany. Br J Ophthalmol 2011; 95: 1061\u20137.","DOI":"10.1136\/bjo.2010.194712"},{"key":"10.3238\/arztebl.2012.0584_ref28","doi-asserted-by":"crossref","unstructured":"Fong DS, Custis P, Howes J, Hsu JW: Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study. Ophthalmology 2010; 117: 298\u2013302.","DOI":"10.1016\/j.ophtha.2009.07.023"},{"key":"10.3238\/arztebl.2012.0584_ref29","doi-asserted-by":"crossref","unstructured":"Gragoudas ES, Adamis AP, Cunningham ET Jr., Feinsod M, Guyer DR: Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805\u201316.","DOI":"10.1056\/NEJMoa042760"},{"key":"10.3238\/arztebl.2012.0584_ref30","doi-asserted-by":"crossref","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, et al.: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419\u201331.","DOI":"10.1056\/NEJMoa054481"},{"key":"10.3238\/arztebl.2012.0584_ref31","doi-asserted-by":"crossref","unstructured":"Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J: Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Arch Ophthalmol 2009; 127: 13\u201321.","DOI":"10.1001\/archophthalmol.2008.562"},{"key":"10.3238\/arztebl.2012.0584_ref32","doi-asserted-by":"crossref","unstructured":"Massin P, Bandello F, Garweg JG, et al.: Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010; 33: 2399\u2013405.","DOI":"10.2337\/dc10-0493"},{"key":"10.3238\/arztebl.2012.0584_ref33","doi-asserted-by":"crossref","unstructured":"Elman MJ, Aiello LP, Beck RW, et al.: Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117: 1064\u201377 e35.","DOI":"10.1016\/j.ophtha.2010.02.031"},{"key":"10.3238\/arztebl.2012.0584_ref34","doi-asserted-by":"crossref","unstructured":"Mitchell P, Bandello F, Schmidt-Erfurth U, et al.: The RESTORE study: ranibizumab monotherapy or combined with laser vers us laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615\u201325.","DOI":"10.1016\/j.ophtha.2011.01.031"},{"key":"10.3238\/arztebl.2012.0584_ref35","doi-asserted-by":"crossref","unstructured":"Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ.: Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897\u2013908.","DOI":"10.1056\/NEJMoa1102673"},{"key":"10.3238\/arztebl.2012.0584_ref36","doi-asserted-by":"crossref","unstructured":"Campochiaro PA, Brown DM, Awh CC, et al.: Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011; 118: 2041\u20139.","DOI":"10.1016\/j.ophtha.2011.02.038"},{"key":"10.3238\/arztebl.2012.0584_ref37","doi-asserted-by":"crossref","unstructured":"Brown DM, Campochiaro PA, Bhisitkul RB, et al.: Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011; 118: 1594\u2013602.","DOI":"10.1016\/j.ophtha.2011.02.022"},{"key":"10.3238\/arztebl.2012.0584_ref38","doi-asserted-by":"crossref","unstructured":"Kuppermann BD, Blumenkranz MS, Haller JA, et al.: Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007; 125: 309\u201317.","DOI":"10.1001\/archopht.125.3.309"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2012.0584","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T04:50:44Z","timestamp":1638852644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2012.0584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,14]]},"references-count":38,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2012.0584","relation":{"is-cited-by":[{"id-type":"doi","id":"10.1155\/2016\/1753584","asserted-by":"object"}]},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,14]]}}}